Study agents | Other agents | Disease | Dosage | Clinical trials | No Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Ibrutinib | Â | Relapsed | 420 mg | Phase I | 14 | CR:14% | [38] |
Refractory | OR:79% | ||||||
Untreated | 420/840 mg | Phase Ib/II | 116 | CR:10/3/0% | [39] | ||
 |  |  | ORR:71/67/50% |  | |||
Ibrutinib | Relapsed/Refractory | ||||||
 |  | High risk |  |  |  |  |  |
Ibrutinib | Rituximab | High risk | 420 mg | Phase II | 40 | ORR:85% | [43] |